These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32679014)

  • 1. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes.
    Denegri A; Boriani G
    Curr Pharm Des; 2021; 27(2):263-275. PubMed ID: 32679014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
    Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options to further lower C-reactive protein for patients on statin treatment.
    Joshi PH; Jacobson TA
    Curr Atheroscler Rep; 2010 Jan; 12(1):34-42. PubMed ID: 20425269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
    Gotto AM
    Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
    Peikert A; Kaier K; Merz J; Manhart L; Schäfer I; Hilgendorf I; Hehn P; Wolf D; Willecke F; Sheng X; Clemens A; Zehender M; von Zur Mühlen C; Bode C; Zirlik A; Stachon P
    Clin Res Cardiol; 2020 Mar; 109(3):315-323. PubMed ID: 31325043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
    Yogo M; Sasaki M; Ayaori M; Kihara T; Sato H; Takiguchi S; Uto-Kondo H; Yakushiji E; Nakaya K; Komatsu T; Momiyama Y; Nagata M; Mochio S; Iguchi Y; Ikewaki K
    Atherosclerosis; 2014 Jan; 232(1):31-9. PubMed ID: 24401214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy.
    Kwon O; Kang SJ; Kang SH; Lee PH; Yun SC; Ahn JM; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Park SW; Park SJ
    Circ Cardiovasc Imaging; 2017 Jul; 10(7):. PubMed ID: 28679524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI; Yu J; Hayashi T; Han SH; Koh KK
    Circ J; 2019 Sep; 83(10):1973-1979. PubMed ID: 31391351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
    Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
    Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
    Ruscica M; Ferri N; Macchi C; Corsini A; Sirtori CR
    Ann Med; 2018 Sep; 50(6):461-484. PubMed ID: 29976096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.